This study aims to systematically evaluate the safety and efficacy of adalimumab combined with paclitaxel, carboplatin, and short-course radiotherapy in the neoadjuvant treatment of esophageal squamous cell carcinoma.
- 1. Provided informed consent and sign the informed consent form;
2. Male or female, Aged 18-75 years (counted on the date of signing informed consent);
3. Pathological confirmed ESCC;
4. Patients assessed by thoracic oncologists as resectable without distant metastasis
1. Patients who have received or are currently receiving chemotherapy, radiotherapy, immunotherapy, or targeted therapy
2. Patients with distant metastasis or inability to undergo resection after evaluation by thoracic surgeons
3. Simultaneously developing tumors in other parts of the body
4. Severe impairment of heart, liver, and kidney function (heart function grade 3-4, ALT and/or AST exceeding the upper limit of normal by more than 1.5 times, Cr (serum creatinine) exceeding the upper limit of normal by more than 1.5 times)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd.
Collaborator